Breast cancer
Conditions
Interventions
TIVA group:Total intravenous anesthesia was used (breast conserving subgroup n = 20, simple mastectomy subgroup n = 20)
SEV group:Sevoflurane inhalation anesthesia was used (breast conserving subgroup n = 20, simple mastectomy subgroup n = 20)
PVB+general group:aravertebral block combined with general anesthesia (breast conserving subgroup n = 20, simple mastectomy subgroup n = 20)
general group:General anesthesia was used (breast conserving subgroup n = 20, simple mastectomy subgroup n = 20)
Sponsors
Shenzhen Hospital, cancer hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients who voluntarily participated in the study and signed a written informed consent; 2. Aged 18 to 60 years old; 3. Histology or cytology confirmed breast adenocarcinoma; 4. The operation of unilateral breast cancer under general anesthesia is proposed; 5. The American Society of Anesthesiology (ASA) was graded grade I or II; 6. Asian race.
Exclusion criteria
Exclusion criteria: 1. Patients with inflammatory diseases; 2. Patients who received surgical treatment in the last 30 days; 3. Pregnant women; 4. Patients with hepatorenal diseases 5. Long term drinking, long-term use of sedative drugs or antidepressants and other mental drugs; 6. There are contraindications of paravertebral nerve block, including severe abnormal coagulation function, infection of puncture site, trauma or spinal operation history; 7. For any reason, the study can not be cooperated with, such as: language understanding difficulties, mental illness, inability to visit hospital for follow-up, etc; 8. Take other trial drugs or participate in other clinical trials within 3 months before the study was selected; 9. Before operation, they were treated with radiotherapy or chemotherapy; 10. The researchers believe that it is not suitable to be included in other cases of this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NLRP3;ASC;pro-caspase-1;caspase-1;IL-1ß;IL-18;pain;Disease free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactSun Li
Shenzhen Hospital, cancer hospital, Chinese Academy of Medical Sciences
Outcome results
None listed